Isavuconazole safe and effective to treat aspergillus infection in patients with cancer
the ONA take:
According to new research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), isavuconazole is as effective as voriconazole for the treatment of aspergillus infection in patients with cancer. In the phase 3 study comparing isavuconazole, new antifungal agent, with voriconazole in patients with uncontrolled cancer, researchers found that the two agents were equally efficacious against the invasive fungal disease.
Furthermore, researchers observed fewer adverse effects associated with isavuconazole versus voriconazole. Compared with those that took voriconzaole, patients who took isavuconazole had less ocular, epidermal, and hepatobiliary toxicity.
Fungal infections caused by aspergillus and other fungi can be particularly harmful in immunocompromised patients undergoing treatment for cancer. These fungal infections often increase morbidity and mortality in these patients, especially those with hematological malignancies like leukemia and lymphoma.
Based on the results of the study, Astellas and Basilea Pharmaceutica International Ltd. have submitted a new drug application to the U.S. Food and Drug Administration (FDA) for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis.
Isavuconazole as effective as voriconazole for treatment of aspergillus infection in patients with cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|